Navigation Links
Cepheid Reports Second Quarter Revenue of $42.1 Million
Date:7/24/2008

Sales and marketing 7,434 5,067 14,375 9,560

General and administrative 5,518 4,038 10,265 7,973

Total costs and operating expenses 49,563 33,154 97,868 65,878

Loss from operations (7,513) (5,981) (10,985) (13,161)

Other income, net 191 740 1,473 1,767

Net loss before income tax benefit (7,322) (5,241) (9,512) (11,394)

Income tax benefit (expense) (204) - 136 -

Net loss $(7,526) $(5,241) $(9,376) $(11,394)

Basic and diluted net loss per share $(0.13) $(0.10) $(0.17) $(0.21)

Shares used in computing basic and

diluted net loss per share 57,054 55,149 56,603 55,081

CEPHEID

CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS

(in thousands)

June 30, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $24,866 $16,476

Marketable securities - 27,550

Accounts receivable, net 18,573 21,263

Inventory 28,505 23,821

Prepaid expenses and other current assets 3,826 2,565

Total current assets 75,770 91,675

Property and equipment, net 22,293 17,174

Investments 21,983 -

Other non-current assets 430 923

Intangible assets 38,319 40,629'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...Iowa, Dec. 4 Vivakor, In... its shareholders of record on December 1, 2009 wi...of HealthAmerica, Inc. that was previously approve...is a private Nevada corporation of which Vivakor o...hares on the record date. The distribution date is...
(Date:12/4/2009)...f., Dec. 4 BlueFire Etha...any focused on changing the world,s transportation...rom non-food cellulosic wastes, has been ranked nu...ottest Companies in Bioenergy;" the company,s seco...voters rank BlueFire Ethanol among the top 20 bioe...
(Date:12/3/2009)...Dec. 3 ACCESS PHARMACE...y provided an update on its European commercial la... mucositis, a debilitating side effect of radiatio...ly launched by Access, partner, SpePharm, in six E...y, Norway, Greece and Sweden. Access is conducting...
(Date:12/3/2009)...lif., Dec. 3 Peregrine P...ced that it will release its financial results for...r 10, 2009 at 7:00 a.m. EST and will host a confer...:30 a.m. EST on the same day. ,, Peregrine,s se... the second quarter ended October 31, 2009 and wil...
Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...RNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ...used on,researching, developing, manufacturing and...t at the UBS Global Life Sciences Conference in Ne...EST. The presentation will be webcast live and ca...rs page of the 3SBio website at, http://bbs.3sbio....
...YSE: DEO ),the world,s leading spirits, wine and ... of a physician,s training program in screening an...edical Society of the State of,New York (MSSNY). ...tricted grant, is,being developed to better prepar...to alcohol abuse. This training program is being d...
...nounces Potential Breakthrough in the ...pt. 17 The British Midlands Development,Corporati...am in the,British Midlands has released a statemen...s C Vaccine. The United Kingdom is home to Europe...s in excess of $8.6 billion per year. In central E...
Other Biology Technology:Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 2Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 3The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 2The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 3
(Date:12/3/2009)... , , WALL, N.J., Dec. 3 /PRNewswire-Fir...in Board: BKYI), a leader in wireless public safet...ons, announced that a majority of its shareholders...ved the sale of the company,s Law Enforcement Divi...res voted, 98.6% were cast in favor and 1.2% were ...
(Date:12/3/2009)... , A coating on windows or solar panels that re...cities for the next electric car? New Tel Aviv Uni...chnology , details a breakthrough in assembling pe...se futuristic visions come true in just a few year...oughly one-billionth of a meter) and even smaller,...
(Date:12/3/2009)... , Grand Rapids, Mich. (Dec. 3, 2009) Van Ande...mined precisely how the plant hormone abscisic aci...s respond to environmental stresses such as drough...nal Nature , could help engineer crops that thriv...t global food shortages. The findings could also ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3A window that washes itself? 2VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Lab Study Makes Strides in Mending Hearts 59283 1Lab Study Makes Strides in Mending Hearts 59283 2Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 1Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 2Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 3Proteolix Inc to be Acquired By Onyx Pharmaceuticals 59278 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 1Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non Alcoholic Steatohepatitis 28NASH 29 14428 6
...,HANOVER, NH -- A team of Dartmouth Medical School...f arsenic disrupt the activity of a hormone critic... that arsenic at low doses (at levels found in U.S...e study appeared in the Oct. 26, 2007, online edit...es (EHP), and it will be published in a forthcomin...
...KLAND, Calif., November 14, 2007 Researchers from...f Public Health, as well as from five other sites ... the largest study to date investigating the genet... and other developmental disabilities. , The five...Early Development, will involve 2,700 children and...
...ium to be Featured in the Biggest Government IT Se...er 2007, SAN JOSE, Nov. 13 Titanium Group, Ltd (...d security solutions provider,announced today that...as,one of the key vendors to showcase their produc...Access Management Seminar and Showcase, to be held...
Other Biology News:Dartmouth researchers show effects of low dose arsenic on development 2Largest study to investigate risk factors of autism to begin enrolling families 2Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar 2Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar 3Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar 4
Tissue Stat from Biomeda Corporation
... proto-oncogene was first identified as the cellul...ne. Jun B and Jun D have been shown to be almost i...ch are involved in dimerization and DNA binding, w...d in transcriptional activation, diverge. Antig...
Mouse Anti-Yersinia pestis Capsular F1 Antigen Monoclonal Antibody, Unconjugated, Clone YBF19 from QED Bioscience Inc.
Rabbit Anti-JMJD2D Polyclonal Antibody, Unconjugated from Abcam
Biology Products: